Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum

145-20-386-WC Website Featured Image (5)
Proprietary Educational Format:

Activity Overview

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

1.00 CE Credit(s)
Expires: December 29, 2021

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Faculty

thomas (1)

Thomas Lodise, PharmD, PhD

Professor
Department of Pharmacy
Albany College of Pharmacy and Health Services
Albany, NY

joe (2) (1)

Joseph Reilly, BS, PharmD, BCGP

Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ

JorgensenSarah_UHN6407 (1)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP

Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada